The full content of Annals is available to subscribers

Subscribe/Learn More  >
Updates |

Update in Nephrology

Stanley Goldfarb, MD
[+] Article, Author, and Disclosure Information

Adapted for publication in Annals of Internal Medicine by Jennifer Fisher Wilson and Michael Berkwits, MD, MSCE.

From the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.

Potential Financial Conflicts of Interest:Consultancies: GE Healthcare, Fresenius. Honoraria: GE Healthcare, Fresenius, AstraZeneca, Omeros. Stock ownership or options (other than mutual funds): Polymedix.

Requests for Single Reprints: Stanley Goldfarb, MD, University of Pennsylvania School of Medicine, Stemmler Hall, Suite 100, 3450 Hamilton Walk, Philadelphia, PA 19104-4283; e-mail, stanley.goldfarb@uphs.upenn.edu.

Ann Intern Med. 2008;148(1):49-54. doi:10.7326/0003-4819-148-1-200801010-00007
Text Size: A A A

The current Update in Nephrology reviews the most important recent articles relevant to those practicing nephrology. The Table summarizes changes to clinical practice that should emerge from these articles.

First Page Preview

View Large
First page PDF preview





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Use of Furosemide in acute renal failure for patients with decompensate cirrhosis
Posted on January 13, 2008
Liu Hong
Institute of Digestive Diseases, Xijing hospital, Fourth Military Medical University, Xi'an, China
Conflict of Interest: None Declared

To the editor:

As Stanley Goldfarb MD reported, Furosemide was not associated with clinical benefit in the prevention and treatment of acute renal failure in adults [1]. Ho KM et al evaluated four kinds of outcomes and drew a conclusion that stopping Furosemide should be a valuable strategy for the prevention or treatment of acute renal failure [2]. However, our clinical data showed that the strategy was doubtful and need upgrade.

Acute renal failure might be one complication of hepatitis B virus infection. From Jan 2007 to Nov 2007, 265 patients (188 men, 77 women, 34- 68 years) with hepatitis B virus-induced decompensate cirrhosis were investigated. Among them, 23 cases were identified as patients with or at risk for acute renal failure. They all suffered from oliguresis (<500 mL/d) and received Furosemide and Spironolactone therapy. The result showed that 74% of them (17/23) benefited from combined therapy of Furosemide and Spironolactone. The average urine output per day significantly increased from <500 mL to > 800 mL. The point was that the combined therapy might be helpful for improving fluid and electrolyte balance and improving the liver functions, thus leading to reversal of renal failure. As for another 242 patients, Furosemide therapy was also proved to be helpful for prevention of acute renal failure by decreasing the amount of ascites and inducing endocrine balance. Thus, Furosemide might be valuable for prevention or treatment of acute renal failure in patients with hepatitis B virus-induced decompensate cirrhosis.

The data sources of Ho KM et al didn't involve the patients with hepatitis B virus-induced decompensate cirrhosis [2]. It might be the reason why their conclusions need upgrade.


1 Stanley G. Update in Nephrology. Ann Intern Med. 2008; 148(1): 49- 54.

2 Ho KM, Sheridan DJ. Meta-analysis of frusemide to prevent or treat acute renal failure. BMJ. 2006; 333(7565): 420.

Conflict of Interest:

None declared

Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.